COVID-19: For information related to COVID-19 (formerly referred to as “novel coronavirus"), visit

VCU Massey Cancer Center


Researcher Steven Grant assumes prestigious roles at the National Cancer Institute

Steven Grant, M.D. [View Image]

World renown for his development of novel drug combinations to treat blood cancers, VCU Massey Cancer Center researcher Steven Grant, M.D., has been asked to serve the National Cancer Institute (NCI) as a member of their Investigational Drug Steering Committee (IDSC) and as IDSC Lymphoma Expert and Liaison to the Lymphoma Steering Committee (LYSC).

Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey, Grant will facilitate many important activities in his role on the IDSC, including conducting strategic discussions about early phase drug development trials, providing initial and ongoing input on clinical development plans for investigational drugs, assessing letters of intent submitted by researchers who wish to carry out clinical trials using Cancer Therapy Evaluation Program (CTEP) investigational drugs and addressing scientific or clinical questions about early stage clinical trials. As IDSC’s Lymphoma Expert and Liaison to the LYSC, Grant will help facilitate communication and collaboration between the IDSC and LYSC.

The IDSC was created in November 2005 and is composed of the Steering Committee, 10 NCI task forces and three NCI working groups. It provides the NCI with scientific and clinical input on the design and prioritization of Phase I and II clinical trials with agents for which CTEP holds an investigational new drug application. The goal of the IDSC is to create more successful Phase III clinical trials by ensuring early phase clinical trials are well designed.

The LYSC was created in 2009 to promote efficient, cost-effective and science-driven clinical research on lymphoma and related diseases by evaluating the design and prioritization of Phase III and large Phase II clinical trials. It is comprised of representatives from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN), AIDS Malignancy Consortium (AMC), Specialized Programs of Research Excellence (SPORE) investigators, community oncologists, biostatisticians, patient advocates and NCI staff.

Written by: John Wallace

Posted on: November 16, 2011

Category: Center news & funding

View graphic versionView graphic version